Tumor site immune markers associated with risk for subsequent basal cell carcinomas |
| |
Authors: | Glaser Ronald Andridge Rebecca Yang Eric V Shana'ah Arwa Y Di Gregorio Michael Chen Min Johnson Sheri L De Renne Lawrence A Lambert David R Jewell Scott D Bechtel Mark A Hearne Dean W Herron Joel Bain Kiecolt-Glaser Janice K |
| |
Institution: | Institute for Behavioral Medicine Research, The Ohio State University Medical Center, Columbus, Ohio, United States of America. Ronald.glaser@osumc.edu |
| |
Abstract: | BackgroundBasal cell carcinoma (BCC) tumors are the most common skin cancer and are highly immunogenic.ObjectiveThe goal of this study was to assess how immune-cell related gene expression in an initial BCC tumor biopsy was related to the appearance of subsequent BCC tumors.Materials and MethodsLevels of mRNA for CD3ε (a T-cell receptor marker), CD25 (the alpha chain of the interleukin (IL)-2 receptor expressed on activated T-cells and B-cells), CD68 (a marker for monocytes/macrophages), the cell surface glycoprotein intercellular adhesion molecule-1 (ICAM-1), the cytokine interferon-γ (IFN-γ) and the anti-inflammatory cytokine IL-10 were measured in BCC tumor biopsies from 138 patients using real-time PCR.ResultsThe median follow-up was 26.6 months, and 61% of subjects were free of new BCCs two years post-initial biopsy. Patients with low CD3ε CD25, CD68, and ICAM-1 mRNA levels had significantly shorter times before new tumors were detected (p?=?0.03, p?=?0.02, p?=?0.003, and p?=?0.08, respectively). Furthermore, older age diminished the association of mRNA levels with the appearance of subsequent tumors.ConclusionsOur results show that levels of CD3ε, CD25, CD68, and ICAM-1 mRNA in BCC biopsies may predict risk for new BCC tumors. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|